Time filter

Source Type

Barcelona, Spain

Moller I.,Rheumatology Institute | Perez M.,Dermatology Institute | Monfort J.,Autonomous University of Barcelona | Benito P.,Autonomous University of Barcelona | And 6 more authors.
Osteoarthritis and Cartilage

Objective: The aim of the trial was to assess the efficacy of chondroitin sulphate (CS) on symptomatic knee osteoarthritis (OA) associated to psoriasis. Methods: In this randomized, double-blind, placebo (PBO)-controlled clinical trial 129 patients with symptomatic knee OA and concomitant psoriasis were randomized into two groups receiving 800. mg daily of CS or PBO for 3 months. The primary efficacy outcome for knee OA was the Huskisson's visual analogue scale (VAS) and for psoriasis was the Psoriasis Area and Severity Index (PASI). Additionally, other secondary efficacy criteria for both conditions were assessed. Results: After 3 months of treatment, CS was more effective than PBO, relieving pain VAS (CS -26.9 ± 24.8 vs PBO -14.23 ± 20.8 mm, P<0.01), decreasing the Lequesne index (CS -4.8 ± 3.4 vs PBO -3.3 ± 3.5, P<0.05) and reducing the number of patients using acetaminophen as rescue medication (CS 43% vs PBO 64%, P<0.05). Regarding PASI, Overall Lesion Severity Scale and Physician's Global Assessment of Change no statistically significant changes were detected in front of PBO. However, CS improved plantar psoriasis compared to PBO (CS 87% vs PBO 27%, P<0.05). Quality of life improved significantly in CS-treated patients according to the Short Form-36 health survey and the Dermatology Life Quality Index (DLQI). CS tolerability was excellent. Adverse events were infrequent and evenly distributed among groups. The incidence of psoriatic flares did not increase after treatments. Conclusions: This study confirms the efficacy and safety of CS as a symptomatic slow-acting drug in patients with knee OA and shows that CS improves plantar psoriasis. The use of CS could represent a special benefit in patients with both pathologies since non-steroidal anti-inflammatory drugs have been reported to induce or exacerbate psoriasis.FDA Clinical Trials Government Identifier: NCT00669123. © 2010 Osteoarthritis Research Society International. Source

Bhatia A.C.,Northwestern University | Bhatia A.C.,Dermatology Institute | Bhatia A.C.,DuPage Medical Group | Jimenez F.,Envy Medical Inc.
Journal of Drugs in Dermatology

The biggest hurdle in the treatment of acne vulgaris is patient non-compliance that is due in large part to poor tolerability to common acne medications. As such, new acne treatments must be developed that balance good anti-acne efficacy with excellent tolerability in order to ensure patient adherence and by extension ensure good clinical outcomes. The goal of the present study was to determine the tolerability and efficacy of a novel skin care system, composed of a cleanser, containing 1% salicylic acid and botanical ingredients, and a treatment gel, containing 1% salicylic acid, 10% buffered glycolic acid and botanical ingredients for the treatment of mild acne. In this single-center, open-label clinical study, 25 male and female volunteers used the test cleanser and test gel twice daily over six weeks. Tolerability assessments showed that the skin care regimen was very well tolerated by all study volunteers. Acne severity was significantly reduced by two acne grades at six weeks. Inflammatory lesion counts were significantly reduced, on average, by 59.06% (P ≤ 0.0001), 91.62% (P ≤ 0.0001), 90.85% (P ≤ 0.0001) and by 98.55% (P ≤ 0.0001) at weeks 1, 2, 4, and 6, respectively. Non-inflammatory lesion counts were reduced, on average, by 13.54% (ns), 38.95% (P ≤ 0.0001), 44.48% (P ≤ 0.0001), and by 56.10% (P ≤ 0.0001) at weeks 1, 2, 4, and 6, respectively. Standardized photography also demonstrated a progressive reduction in acne lesions over time. In conclusion, results of the present study suggest that the tested skin care regimen offers rapid acne clearance and excellent tolerability that together may help to improve patient adherence as well as treatment outcome. Copyright © 2014. Source

Zhang C.,Burns Institute | Chen P.,Beijing Institute of Radiation Medicine | Fei Y.,Burns Institute | Liu B.,Burns Institute | And 5 more authors.
Aging Cell

Aged epidermal cells have the capacity to dedifferentiate into stem cell-like cells. However, the signals that regulate the dedifferentiation of aged epidermal cells remain unclear. Here, we provide evidence that Wnt/β-catenin is critical for aged epidermal cell dedifferentiation in vivo and in vitro. Some aged epidermal cells in human ultrathin epidermal sheets lacking basal stem cells transplanted onto wounds dedifferentiated into stem cell-like cells that were positive for CK19 and β1 integrin but negative for CK10. In addition, Wnt/β-catenin pathway was activated during this process. There was increased expression of Wnt-1, Wnt-4, Wnt-7a, β-catenin, cyclin D1, and c-myc. Secreted frizzled-related protein 1, a Wnt/β-catenin pathway inhibitor, blocked dedifferentiation in vivo. Then, the activator, a highly specific glycogen synthase kinase (GSK)-3β inhibitor, of Wnt/β-catenin pathway was added to the culture medium of aged epidermal cells. Surprisingly, we found that the activator induced higher expression of CK19, β1 integrin, Oct4, and Nanog proteins. The induced aged epidermal cells exhibited high colony-forming efficiency, long-term proliferative potential and could regenerate a skin equivalent (as do epidermal stem cells). These results suggested that activation of Wnt/β-catenin pathway induced the dedifferentiation of aged epidermal cells, which suggest a new approach to generate epidermal stem cell-like cells. © 2011 The Authors. Aging Cell © 2011 Blackwell Publishing Ltd/Anatomical Society of Great Britain and Ireland. Source

Rullan P.,Dermatology Institute | Karam A.M.,University of California at San Diego
Facial Plastic Surgery Clinics of North America

This article focuses on chemical peels for darker skin types. All races comprise a range of Fitzpatrick skin color types: light skin types in African Americans, Asians, Middle Easterners, and Latinos and dark skin types in whites. With the focus on Fitzgerald skin types IV to VI, this article discusses chemical peels, providing current information on types of peels, detailed techniques, preoperative and postoperative care, complications, hazards, and nuances of management. © 2010 Elsevier Inc. All rights reserved. Source

Yamauchi P.S.,Dermatology Institute | Yamauchi P.S.,University of California at Los Angeles
Giornale Italiano di Dermatologia e Venereologia

A variety of non-invasive techniques have been utilized for the enhancement of cutaneous changes seen with photoaging. Such methods include chemical peels, microdermabrasion, ablative and nonablative lasers, and various rejuvenating light sources. However, the most widely used minimally invasive cosmetic procedures for the correction of undesired rhytides and enhance facial features through contouring and volumization are injections with botulinum toxin and soft tissue fillers. Their extensive long term safety and relative ease of procedural techniques have led to high satisfaction levels worldwide. Nonetheless, proper training of the fundamentals in injection technique, the choice of the appropriate candidate, and knowledge of potential adverse events are imperative to ensure an excellent and safe outcome. Source

Discover hidden collaborations